ArticleTransboundary and emerging diseases2025
Screening and Identification of Multiple Peptides Homologous to the Fusion Glycoprotein Gc of Schmallenberg Virus Able to Inhibit Viral Infection.
Article in Transboundary and emerging diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Design and Characterization of an HRC-Derived Peptide Inhibitor of Canine Coronavirus Spike-Mediated Fusion.Pathogens (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arthropod-borne viruses have been responsible for several emerging infections, causing a global issue in both human and veterinary fields. Within the Orthobunyaviruses, a novel and major member is the Schmallenberg virus (SBV) first detected in central Europe in 2011, and soon after was able to spread all over the continent by causing severe infection in ruminants, leading to abortion and congenital malformations. The viral particle is surrounded by a membrane in which two glycoproteins (Gn and Gc) mediate the entry, mainly through the class II fusion protein Gc, but this event requires the presence of Gn. Therefore, Gn and Gc may represent a target for antiviral development. In our study, we evaluated the inhibitory effect mediated by overlapping peptides designed on the amino acid sequences of Gc and Gn and spanning their entire length. A brute analysis of both glycoproteins was performed to explore the inhibitory effect of such peptides against SBV infection. Five out of 63 Gc peptides at a concentration of 100 μM reached 50% of inhibition and, interestingly, they are mainly distributed near the C-terminal domain. None of the 20 Gn peptides inhibited the infection, and no peptide toxicity was observed. Our findings could identify new putative domains, located at the C-terminal of Gc, in the process of SBV penetration; therefore, these results are relevant to the potential development of novel therapeutic agents for the treatment of SBV infections and could serve as a model for many human pathogens belonging to the same family.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.